Evidence map›Paper›PMID 41150584›Full record

ArticleToxics2025

The PFAS Conundrum-Of Logic, Science, Policy.

Jaap C Hanekamp, Lucas Bergkamp, William M Briggs, Moira Wilson

Abstract read
In one paragraph

Article in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jaap C HanekampIndependent Researcher, 2725 NA Zoetermeer, The Netherlands.ORCID 0000-0002-6575-3658
Lucas BergkampIndependent Researcher, 1000 Brussels, Belgium.
William M BriggsIndependent Researcher, Charlevoix, MI 49700, USA.
Moira WilsonCertified Group, 3436 ZZ Nieuwegein, The Netherlands.ORCID 0009-0001-8435-8725

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The comprehensive ("universal") PFAS ban proposed by the EU raises questions of a scientific, philosophical, regulatory, and policy nature. This overview scrutinizes the proposal and finds it wanting in each of these respects. The grouping of all PFAS is based on a methodology that is only loosely science based. The scientific data on PFAS do not support the open-ended definition and the drastic restrictions that would be imposed by the proposal. To illustrate the weak scientific basis, we look more closely at the immunotoxicity claims as found in a few landmark epidemiological papers. We find these claims not well-founded and methodologically lacking. Also, we scrutinize a few animal studies and comment on their results. Detecting PFAS in multiple matrices is briefly looked at. The analytical context of detectability, quantifiability, measurement precision, and reproducibility of results of PFAS present in especially complex matrices (e.g., foods, soil, waxes, and fats) poses quite the challenge. Experimental uncertainties are reported to be extremely high. Disregarding the key distinctions between hazard and risk and between potential hazard and hazard, the proposal treats all PFASs, broadly defined, as presenting hazards based on an assumed common property: persistence. On this and other grounds, including the requirement of "unacceptable risk", the proposed ban fails to meet the requirements imposed by the REACH Regulation. From a public policy perspective, the costs of the proposal would appear to eclipse any advantages for human health and the environment. Thus, we conclude that the proposed PFAS ban is problematic from these key perspectives.

Indexed as

chemical banchemistryPFASREACHrestrictions of hazardous substancestoxicology

Identifiers

PMID41150584
PMCPMC12568048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.